Monitor for any reverse stock split or capital raise to boost MVLS above $35M; delisting is a binary risk by mid-December. The Launxp dispute adds overhang — watch for resolution within the 30-day negotiation period. Vebreltinib rights recovery is structurally positive but secondary to the solvency and listing threats.
Price Chart
Executive Summary
Apollomics received a Nasdaq deficiency notice for failing to maintain the minimum $35 million Market Value of Listed Securities, with a 180-day cure period until December 15, 2026. Separately, it terminated its license deal with Launxp for non-payment of a $3.8 million balance, regaining full ex-China/Macau rights to lead asset vebreltinib, and initiated dispute resolution. The delisting risk is material, but the license recovery offers a path to re-license vebreltinib on better terms.
Key Facts
- Nasdaq deficiency notice for minimum MVLS of $35M; 180-day compliance period ends December 15, 2026
- Company does not meet alternative listing standards (5550(b)(1) and 5550(b)(3))
- Formally terminated Launxp license agreement effective June 11, 2026 for failure to pay $3.8M upfront balance
- Initiated dispute resolution on June 18, 2026; Launxp publicly disagreed with termination
- Regained full ex-China/Macau rights to vebreltinib (APL-101), consolidating global ownership outside Mainland China and Macau
- 20-F filed April 24, 2026 reported net loss of $10.9M for 2025, cash of $3.3M, substantial doubt about going concern
Financial Impact
Launxp owed $3.8M; recovery uncertain. Insufficient cash ($3.3M as of Dec 2025) to meet obligations. Delisting risk if MVLS does not reach $35M by Dec 15, 2026.
Risk Factors
- Failure to regain Nasdaq compliance by December 15, 2026 could lead to delisting and loss of public trading
- Only $3.3M cash as of year-end 2025 with substantial doubt about going concern
- Dispute with Launxp may delay or impair recovery of $3.8M and create legal costs
- Limited pipeline; vebreltinib still in Phase 2 with no near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-281262 |
| Document: d137400dex991.htm | 0001193125-26-281262 |
| Document: 0001193125-26-281262-index-headers.html | 0001193125-26-281262 |
| Document: 0001193125-26-281262-index.html | 0001193125-26-281262 |
| Document: 0001193125-26-281262.txt | 0001193125-26-281262 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 10w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $21.84 (−8.70%) |
Aug 17, 2026 10w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $21.84 (−8.70%) |
Aug 17, 2026 10w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $21.84 (−8.70%) |
Aug 17, 2026 10w ago | Insider Cluster | $23.92 $26.50 | ▲ +10.79% | ▲ +10.99% | $21.84 (−8.70%) |
Jul 21, 2026 13w ago | 6-K | $18.71 $18.00 | ▼ −3.77% | ▼ −2.54% | $21.84 (+16.76%) |
Jul 14, 2026 14w ago | 6-K | $15.70 $18.86 | ▲ +20.13% | ▲ +21.42% | $21.84 (+39.11%) |
Jun 24, 2026 17w ago | 6-K | $22.00 $20.16 | ▲ +8.36% | ▲ +9.92% | $21.84 (+0.73%) |
Apr 27, 2026 26w ago | Press Release | $13.19 $16.47 | ▲ +24.84% | ▲ +24.44% | $21.84 (+65.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers